Jacques Raphael

Congrats to C.Jia MSc graduate @SchulichMedDent for his RWE poster #ESMO25 looking at outcomes of patients treated with ribociclib & palbociclib @ICESOntario

The role of gut microbiota as a potential biomarker for first-line treatment selection in NSCLC has remained unclear. This biomarker study from the Phase III NIPPON trial by Hakozaki et al. provides new insights into this topic. Read now ➡️ bit.ly/451nKub

Diogo Jota 🧡❤️

Well done, Canada

Hady Habib does it! Two days ago Lebanon had never had a Grand Slam main draw participant, now they have a match winner! And look at what it means! He defeats Bu 7-6(4) 6-4 7-6(6) @wwos • @espn • @eurosport • @wowowtennis • #AusOpen • #AO2025

“War cannot be humanized, only abolished” (A. Einstein)

THE EDMONTON OILERS HAVE FORCED A #GAME7!!!! 🤩 #StanleyCup

A study by @JackRaph et al. shows early mortality is common among patients with cancer treated with immunotherapy. The study suggests the need for a predictive tool to improve patient selection for ICI treatment in routine clinical practice. Read here: doi.org/10.1093/jnci/d…

“A cancer patient. A cancer case. Common terms, but ones that can have a great impact on patients and their mental health.” A new @TheLancetOncol Editorial discusses person-first language and treating patients with respect at every turn: hubs.li/Q024gWnc0

#CAMO23 Congratulations👏 to Dr. Nupur Krishnan for Best Poster Presentation➡️Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis @GillSharlene @camoprez @z_veitch

ICES welcomes @JackRaph as a new scientist! Jacques' work includes conducting health services research, systematic reviews, and meta-analyses. Learn more about his research bit.ly/40FsAZY

The European Organisation for Research and Treatment of Cancer (@EORTC) endorses #TargetTrial emulation with #RWD. An organization with unmatched expertise in the design of #randomizedtrials embraces their explicit emulation when using observational data. ejcancer.com/article/S0959-…

Important study. 1/5 pts over age 65 receiving std adj chemo received low relative dose intensity and had INFERIOR outcome. Reducing dose is not the first solution, choice of regimen, growth factors and supportive care are critical. @OncoAlert

Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…

Review of pathologic complete response (pCR) shows that evidence currently available does not support pCR used alone as a reliable surrogate endpoint in neoadjuvant randomized controlled trials for breast cancer. ja.ma/3En94dh #BCSM

🎯Interesting study on pre-existing autoimmune disease in pts treated with anti-PD-1👏 @JNCI_Now doi.org/10.1093/jnci/d… ✅17 497 pts, retrosp. ✅Risk of mortality not ⬆️ ✅some cases w favorable prognosis 👉underlying AD may not be a contraindication for IO @myESMO @OncoAlert

Analysis of overall survival data from the IMpower010 trial shows overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage II-IIIA population but not in the all randomized stage II-IIIA or intent-to-treat population per research presented today at #WCLC22. #LCSM

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA #NSCLC. Today at #WCLC22, the researchers from the NADIM trial presented new data that supports the conclusions of the initial NADIM trial. #LCSM